Diagnostic performances of leucine-rich α-2-glycoprotein 1 and stem cell factor for diagnosis and follow-up of colorectal cancer

Fouda, Manar S.; Aljarwani, Rokaia M.; Aboul-Enein, Khaled; Omran, Mohamed M.

doi:10.1186/s43141-021-00116-3

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positively correlates with tumour stage and size [ 184 , 191 , 193 , 228 , 229 ] Serum In conjunction with other biomarkers, suggested as diagnostic, prognostic, and follow-up factor. Associated with altered glycosylation [ 13 , 230 – 233 ] Tumour tissue Associated with cancer aggressiveness and vascular density. Proposed as diagnostic in general and prognostic for stage III colorectal cancer [ 180 , 184 , 197 ] Stool In conjunction with Hp, SYNE2, RBP4, FN1 and ANXA6, suggested for early detection of high-risk adenomas and colorectal cancer [ 234 ] Endometrial Tumour tissue Suggested as independent prognostic factor of stage and lymphatic metastasis [ 235 ] Esophageal Plasma Significantly elevated in esophageal squamous cell carcinoma and, in conjunction with alpha-2-HS-glycoprotein, proposed as biomarker for early diagnosis [ 236 ] Tumour tissue Closely correlated with worse clinical survival [ 237 ] Serum In combination with CRP and sIL-6R, suggested as biomarker to predict response to preoperative chemoradiotherapy [ 238 ] Gastric Serum and tumour tissue Proposed as prognostic factor.…”

Section: Reviewmentioning

confidence: 99%

LRG1: an emerging player in disease pathogenesis

et al. 2022

View full text Add to dashboard Cite

The secreted glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1) was first described as a key player in pathogenic ocular neovascularization almost a decade ago. Since then, an increasing number of publications have reported the involvement of LRG1 in multiple human conditions including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. The purpose of this review is to provide, for the first time, a comprehensive overview of the LRG1 literature considering its role in health and disease. Although LRG1 is constitutively expressed by hepatocytes and neutrophils, Lrg1−/− mice show no overt phenotypic abnormality suggesting that LRG1 is essentially redundant in development and homeostasis. However, emerging data are challenging this view by suggesting a novel role for LRG1 in innate immunity and preservation of tissue integrity. While our understanding of beneficial LRG1 functions in physiology remains limited, a consistent body of evidence shows that, in response to various inflammatory stimuli, LRG1 expression is induced and directly contributes to disease pathogenesis. Its potential role as a biomarker for the diagnosis, prognosis and monitoring of multiple conditions is widely discussed while dissecting the mechanisms underlying LRG1 pathogenic functions. Emphasis is given to the role that LRG1 plays as a vasculopathic factor where it disrupts the cellular interactions normally required for the formation and maintenance of mature vessels, thereby indirectly contributing to the establishment of a highly hypoxic and immunosuppressive microenvironment. In addition, LRG1 has also been reported to affect other cell types (including epithelial, immune, mesenchymal and cancer cells) mostly by modulating the TGFβ signalling pathway in a context-dependent manner. Crucially, animal studies have shown that LRG1 inhibition, through gene deletion or a function-blocking antibody, is sufficient to attenuate disease progression. In view of this, and taking into consideration its role as an upstream modifier of TGFβ signalling, LRG1 is suggested as a potentially important therapeutic target. While further investigations are needed to fill gaps in our current understanding of LRG1 function, the studies reviewed here confirm LRG1 as a pleiotropic and pathogenic signalling molecule providing a strong rationale for its use in the clinic as a biomarker and therapeutic target.

show abstract

Section: Reviewmentioning

confidence: 99%

LRG1: an emerging player in disease pathogenesis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, LRG1 served as a biomarker to detect early high-risk adenomas as well as colorectal cancer (Sun et al, 2017;Komor et al, 2020;Kopylov , 2020). significantly decreased combined indexes of stem cell factor, LRG1, and platelet lymphocyte ratio could be detected in nontreated colorectal cancer patients (Fouda et al, 2021). Basic research results suggested that LRG1 promoted the cellular proliferation and apoptosis by modulating runt-related transcription factor 1 expression in colorectal cancer (Zhou et al, 2017).…”

Section: Part Four: Lrg1 Involved In Tumor Diseasesmentioning

confidence: 94%

Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review

Zou

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter transfer and release, and cell adhesion molecules or ligand-binding proteins. Also, LRG1 affected the development of respiratory diseases, hematological diseases, endocrine diseases, tumor diseases, eye diseases, cardiovascular diseases, rheumatic immune diseases, infectious diseases, etc. LRG1 was a newly discovered important upstream signaling molecule of transforming growth factor⁃β (TGF⁃β) that affected various pathological processes through the TGF⁃β signaling pathway. However, research on LRG1 and its involvement in the occurrence and development of diseases was still in its infancy and the current studies were mainly focused on proteomic detection and basic animal experimental reports. We could reasonably predict that LRG1 might act as a new direction and strategy for the treatment of many diseases.

show abstract